AngioScore develops the AngioSculpt Percutaneous Transluminal Coronary and Peripheral Angioplasty (PTCA/PTA) scoring balloon catheters. The company has received regulatory clearance to market its Coronary and Peripheral AngioSculpt catheters in the U.S., Europe and Japan. AngioSculpt catheters have been used in more than 100,000 procedures worldwide, and the company cites a market of well over 3 million annual angioplasty procedures globally. AngioScore is pursuing product expansion with programs including a 100mm AngioSculpt for peripheral artery disease, a drug-coated AngioSculpt, and a variant for valvuloplasty and to facilitate TAVI procedures. Management says the financing will support these new product development programs and further enhance the company’s revenue growth over recent years. The company is privately held and located in Fremont, California.

Total raised

$12M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2011